Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AXDX

AXDX - Accelerate Diagnostics Inc Stock Price, Fair Value and News

0.95USD+0.04 (+4.40%)Market Closed
Watchlist

Market Summary

USD0.95+0.04
Market Closed
4.40%

AXDX Stock Price

View Fullscreen

AXDX RSI Chart

AXDX Valuation

Market Cap

13.2M

Price/Earnings (Trailing)

-0.21

Price/Sales (Trailing)

1.1

EV/EBITDA

0.12

Price/Free Cashflow

-0.32

AXDX Price/Sales (Trailing)

AXDX Profitability

EBT Margin

-524.94%

Return on Equity

-9.49%

Return on Assets

-160.79%

Free Cashflow Yield

-316.61%

AXDX Fundamentals

AXDX Revenue

Revenue (TTM)

12.0M

Rev. Growth (Yr)

11.45%

Rev. Growth (Qtr)

12.94%

AXDX Earnings

Earnings (TTM)

-63.2M

Earnings Growth (Yr)

105.72%

Earnings Growth (Qtr)

102.78%

Breaking Down AXDX Revenue

Last 7 days

-1.7%

Last 30 days

-68.1%

Last 90 days

-76.9%

Trailing 12 Months

-80.8%

How does AXDX drawdown profile look like?

AXDX Financial Health

Current Ratio

0.86

AXDX Investor Care

Shares Dilution (1Y)

46.83%

Diluted EPS (TTM)

-6.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202312.6M11.7M12.0M0
202212.2M13.3M13.1M12.8M
202111.3M12.0M11.5M11.8M
20209.9M10.2M11.5M11.2M
20196.6M6.7M7.6M9.3M
20184.4M5.4M6.0M5.7M
2017613.0K1.3M2.1M4.2M
2016224.0K226.0K229.0K246.0K
2015122.0K127.0K132.0K75.0K
201446.0K52.0K55.0K122.0K
201380.0K41.0K48.2K48.0K
2012240.8K238.4K236.0K158.0K
201100244.5K243.3K
20100000

Tracking the Latest Insider Buys and Sells of Accelerate Diagnostics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
phillips jack
acquired
-
-
1,000
chief executive officer
Feb 01, 2024
phillips jack
sold
-642
1.3
-494
chief executive officer
Jan 23, 2024
massarany hany
bought
-
-
16,666
-
Jan 23, 2024
schuler jack w
acquired
-
-
1,156,070
-
Jan 23, 2024
strobeck matthew
bought
-
-
100,000
-
Jan 23, 2024
francesconi louise
bought
-
-
13,333
-
Jan 23, 2024
patience david
acquired
-
-
16,666
chief financial officer
Jan 23, 2024
phillips jack
acquired
-
-
16,666
chief executive officer
Jan 23, 2024
patience john
bought
-
-
16,666
-
Dec 13, 2023
patience david
sold
-425
4.39
-97.00
chief financial officer

1–10 of 50

Which funds bought or sold AXDX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
new
-
54,672
54,672
-%
Feb 14, 2024
VANGUARD GROUP INC
added
1.18
-540,630
1,202,020
-%
Feb 14, 2024
ORACLE INVESTMENT MANAGEMENT INC
reduced
-18.28
-347,662
437,374
0.27%
Feb 14, 2024
Royal Bank of Canada
added
12.2
-11,000
37,000
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
60,548
60,548
-%
Feb 14, 2024
STATE STREET CORP
unchanged
-
-43,069
92,257
-%
Feb 14, 2024
Tudor Investment Corp Et Al
unchanged
-
-25,829
55,327
-%
Feb 14, 2024
BARTLETT & CO. WEALTH MANAGEMENT LLC
reduced
-50.00
-750
400
-%
Feb 14, 2024
Alyeska Investment Group, L.P.
sold off
-100
-712,413
-
-%

1–10 of 39

Are Funds Buying or Selling AXDX?

Are funds buying AXDX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AXDX
No. of Funds

Unveiling Accelerate Diagnostics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 20, 2023
schuler jack w
40.6%
58,012,207
SC 13D/A
Jun 20, 2023
indaba capital management, l.p.
9.9%
15,972,241
SC 13D
Jun 08, 2023
schuler jack w
19.99%
20,260,952
SC 13D/A
Feb 24, 2022
feinberg larry n
4.97%
3,257,503
SC 13G/A
Feb 11, 2022
feinberg larry n
5.53%
3,627,549
SC 13G/A
Dec 03, 2021
schuler jack w
26.4%
18,409,240
SC 13D/A
Oct 05, 2021
schuler jack w
25.7%
17,186,959
SC 13D/A
Feb 16, 2021
feinberg larry n
6.67%
3,806,139
SC 13G/A
Feb 12, 2021
credit suisse ag/
3.10%
1,765,390
SC 13G/A
Feb 14, 2020
feinberg larry n
8.59%
4,696,652
SC 13G/A

Recent SEC filings of Accelerate Diagnostics Inc

View All Filings
Date Filed Form Type Document
Feb 27, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Jan 25, 2024
4
Insider Trading
Jan 25, 2024
4
Insider Trading
Jan 25, 2024
4
Insider Trading
Jan 25, 2024
4
Insider Trading
Jan 25, 2024
4
Insider Trading
Jan 25, 2024
4
Insider Trading
Jan 25, 2024
4
Insider Trading
Jan 25, 2024
8-K
Current Report

Peers (Alternatives to Accelerate Diagnostics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
207.9B
40.1B
0.08% 5.41%
36.32
5.18
-8.12% -17.45%
69.7B
19.5B
1.90% -2.48%
55.46
3.57
4.02% -22.04%
24.0B
3.8B
13.67% -2.23%
66.09
6.3
-1.48% -28.97%
21.3B
14.9B
3.05% 1.38%
8
1.42
2.01% 209.17%
MID-CAP
10.1B
12.7B
2.56% -12.12%
22.73
0.8
0.68% -30.25%
9.7B
2.7B
6.89% -27.73%
-15.19
3.63
-4.68% 82.43%
9.3B
3.5B
8.76% 25.90%
32.56
2.66
4.97% 18.89%
7.1B
3.9B
-8.15% -6.44%
-32.58
1.81
-2.62% 73.16%
3.5B
342.6M
-1.40% 20.18%
-288.47
10.1
42.19% 84.12%
2.7B
6.6B
-4.32% -4.67%
13.38
0.41
2.61% 0.52%
SMALL-CAP
993.4M
3.2B
8.08% -63.68%
-1.47
0.31
7.73% -1066.14%
369.8M
163.3M
8.18% -20.52%
-15.05
2.26
7.14% -56.09%
238.7M
329.5M
3.17% -52.24%
-16.91
0.72
0.49% 64.22%
77.6M
50.3M
4.50% -30.54%
-5.12
1.54
3.23% 20.81%
4.6M
3.7M
-15.66% 215.09%
-0.37
1.22
5.77% 8.23%

Accelerate Diagnostics Inc News

Latest updates
InvestorsObserver29 Jan 202408:00 am
MarketWatch19 Jan 202408:00 am

Accelerate Diagnostics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue12.9%3,299,0002,921,0002,812,0002,973,0002,960,0003,861,0002,958,0003,344,0003,122,0002,798,0002,518,0003,110,0003,588,0002,125,0002,342,0003,470,0002,271,0001,806,0001,750,0001,822,0001,355,000
Gross Profit-86.6%107,000799,0001,011,000842,000579,0001,080,000802,000-3,317,000986,0001,053,000897,0001,149,0001,301,000954,0001,055,0001,513,0001,154,000899,000834,000524,000675,000
Costs and Expenses10.3%14,757,00013,384,00017,073,00014,801,50015,540,00019,069,00016,697,00016,094,00015,518,00018,643,00020,924,00016,229,50016,466,00016,679,00018,785,00019,783,00018,807,00018,986,00019,656,00020,283,00020,044,000
  S&GA Expenses2.6%7,761,0007,564,00010,105,0008,771,5008,255,00011,493,00010,673,00011,491,50010,806,00012,910,00014,029,00011,165,00011,465,00011,332,00012,943,00013,583,50012,743,00012,837,00012,723,00013,378,50012,153,000
  R&D Expenses20.2%6,996,0005,820,0006,968,0006,030,0007,285,0007,576,0006,024,0004,602,5004,712,0005,733,0006,895,0005,064,5005,001,0005,347,0005,842,0006,199,5006,064,0006,149,0006,933,0006,904,5007,891,000
EBITDA Margin24.0%-4.98-6.55-4.89-4.47-5.28-4.42-4.80-5.67-5.71-6.32-6.49-6.35---------
Interest Expenses-----351,500713,0001,506,000-4,095,0004,211,0004,177,0004,090,000-7,251,5003,955,0003,835,0003,749,0003,671,0003,598,0003,528,0003,459,000-16,833,0003,357,000
Income Taxes-16.0%131,000156,000--77,000---45,000---5,000----110,500-239,00017,000221,000-221,000147,000
Earnings Before Taxes103.2%1,041,000-32,579,000-16,795,000-14,686,000-15,896,000-18,523,000-13,465,000-22,758,000-8,986,000-21,674,000-24,239,000-18,907,000-18,757,000-19,230,000-21,309,000-21,445,500-20,673,000-20,798,000-21,500,000-22,412,000-21,951,000
EBT Margin23.4%-5.25-6.85-5.23-4.91-5.38-4.80-5.47-6.59-6.39-6.96-7.15-7.00---------
Net Income102.8%910,000-32,735,000-16,795,000-14,609,000-15,896,000-18,523,000-13,465,000-22,803,000-8,986,000-21,674,000-24,239,000-18,912,000-18,757,000-19,230,000-21,309,000-21,335,000-20,434,000-20,815,000-21,721,000-22,191,000-22,098,000
Net Income Margin23.2%-5.27-6.86-5.22-4.90-5.39-4.80-5.48-6.59-6.39-6.96-7.15-7.00---------
Free Cashflow24.4%-8,212,000-10,861,266-13,473,266-9,595,266-13,646,266-13,072,266-12,679,266-12,020,266-12,521,266-9,626,266-13,448,266-10,416,266---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-21.2%39.0050.0051.0065.0076.0059.0070.0083.0081.0094.0093.0093.00104115120134147159172185201
  Current Assets-23.2%32.0042.0043.0056.0066.0048.0061.0073.0072.0084.0082.0082.0092.00103107122134150164178193
    Cash Equivalents-31.1%20.0029.0029.0035.0039.005.0014.0040.0036.0045.0043.0036.0027.0047.0039.0061.0093.0087.0075.0066.0062.00
  Inventory-30.4%4.005.005.005.005.005.006.005.0010.0010.0010.009.009.009.009.008.008.008.009.008.009.00
  Net PPE-9.9%3.003.003.003.004.004.005.005.005.006.006.006.007.008.009.008.009.008.007.007.007.00
Liabilities-16.0%74.0089.0090.0087.0086.00121126118121164159156154152143142137133129128123
  Current Liabilities-29.7%38.0054.0068.0067.0066.0067.001147.008.009.007.007.007.0010.007.008.006.008.006.008.005.00
  Long Term Debt------50.009.00108110147144141138135133130127125122120118
    LT Debt, Current0%1.001.0057.0056.0056.0056.00106-0.001.001.001.001.002.00-------
    LT Debt, Non Current------50.009.00108110147144141138135133130127125122120118
Shareholder's Equity0.4%66666463163062856054758155351449647546946345845210.0044444057.0077.00
  Retained Earnings0.1%-655-656-624-607-592-576-558-570-547-538-517-492-474-455-436-414-393-372-352-330-308
  Additional Paid-In Capital0.4%666664631630628560547581553514496475469463458452449444440433431
Shares Outstanding1.0%15.0014.0010.0010.009.007.007.007.006.006.006.006.00---------
Float------53.00---320---480---714---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations23.9%-8,212-10,788-13,400-9,522-13,573-12,999-12,606-11,947-12,448-9,553-13,375-10,343-12,656-9,798-17,597-13,865-17,367-14,057-19,505-14,326-18,013
  Share Based Compensation9.8%1,8151,6535552,4461,2293,9712,9792,9893,6296,5908,8394,1734,6763,4164,1993,2093,1312,8813,3971,9463,465
Cashflow From Investing-138.7%-3549158,2095,84215,7884,428-13,641-2,7502,789-2578,52217,852-9,93811,048-5,356-18,65321,29425,37124,79918,84211,722
Cashflow From Financing-108.3%-8179,806-77.00-12632,036-35777.0018,89183011,65011,8551,3402,2556,6091,4295811,6228043,8161751,124
  Buy Backs--------20,2973.00------------

AXDX Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Net sales$ 3,299$ 2,960$ 9,032$ 9,780
Cost of Goods and Services Sold [Abstract]    
Cost of sales2,0082,3815,9317,318
Inventory write-down1,18401,1840
Total cost of sales3,1922,3817,1157,318
Gross profit1075791,9172,462
Costs and expenses:    
Research and development6,9967,28519,78320,885
Sales, general and administrative7,7618,25525,43230,422
Total costs and expenses14,75715,54045,21551,307
Loss from operations(14,650)(14,961)(43,298)(48,845)
Other income (expense):    
Gain on fair value adjustment18,056013,0260
Foreign currency exchange gain(428)(261)(170)(221)
Interest income24673921151
Other (expense) income, net(29)(49)56(206)
Total other income (expense), net15,691(935)(5,036)961
Net income (loss) before income taxes1,041(15,896)(48,334)(47,884)
Provision for income taxes(131)0(286)0
Net income (loss)$ 910$ (15,896)$ (48,620)$ (47,884)
Basic net income (loss) per share (in usd per share)$ 0.06$ (1.83)$ (4.13)$ (6.21)
Basic weighted average shares outstanding (in shares)14,4338,70111,7777,705
Dilutive net income (loss) per share (in usd per share)$ 0.06$ (1.83)$ (4.13)$ (6.21)
Dilutive weighted average shares outstanding (in shares)14,5538,70111,7777,705
Other comprehensive loss:    
Net income (loss)$ 910$ (15,896)$ (48,620)$ (47,884)
Net unrealized gain (loss) on debt securities available-for-sale04828(84)
Foreign currency translation adjustment29313912(101)
Comprehensive income (loss)1,203(15,709)(48,580)(48,069)
Nonrelated Party    
Other income (expense):    
Interest expense(2,205)(203)(3,798)(1,833)
Gain (loss) on extinguishment of debt510(6,499)3,565
Related Party    
Other income (expense):    
Interest expense0(495)(1,817)(495)
Gain (loss) on extinguishment of debt$ 0$ 0$ (6,755)$ 0

AXDX Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 20,162$ 34,905
Investments98910,656
Trade accounts receivable, net2,6662,416
Inventory3,5535,194
Prepaid expenses1,435818
Other current assets3,6382,025
Total current assets32,44356,014
Property and equipment, net2,6093,478
Finance lease assets, net1,8072,422
Operating lease right of use assets, net1,3521,859
Other non-current assets1,1131,242
Total assets39,32465,015
Current liabilities:  
Accounts payable4,8124,501
Accrued liabilities3,4372,682
Accrued interest1,186472
Deferred revenue596547
Current portion of convertible notes72656,413
Finance lease, current4681,113
Operating lease, current963829
Derivative liability25,5980
Total current liabilities37,78666,557
Finance lease, non-current270782
Operating lease, non-current8161,545
Deferred income, non-current1,0900
Other non-current liabilities1,068874
Accrued interest related-party0663
Long-term debt related-party016,858
Convertible notes, non-current33,3270
Total liabilities74,35787,279
Commitments and contingencies (see Note 14)
Stockholders’ deficit:  
Preferred shares, $0.001 par value; 5,000,000 preferred shares authorized with no shares issued and outstanding on September 30, 2023 and 5,000,000 preferred shares authorized with 3,954,546 shares issued and outstanding on December 31, 202204
Common stock, $0.001 par value; 450,000,000 common shares authorized with 14,504,695 shares issued and outstanding on September 30, 2023 and 200,000,000 common shares authorized with 9,747,755 shares issued and outstanding on December 31, 20221410
Contributed capital666,239630,428
Treasury stock(45,067)(45,067)
Accumulated deficit(655,859)(607,239)
Accumulated other comprehensive loss(360)(400)
Total stockholders’ deficit(35,033)(22,264)
Total liabilities and stockholders’ deficit$ 39,324$ 65,015
AXDX
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.
 CEO
 WEBSITEacceleratediagnostics.com
 EMPLOYEES179

Accelerate Diagnostics Inc Frequently Asked Questions


What is the ticker symbol for Accelerate Diagnostics Inc? What does AXDX stand for in stocks?

AXDX is the stock ticker symbol of Accelerate Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Accelerate Diagnostics Inc (AXDX)?

As of Tue Feb 27 2024, market cap of Accelerate Diagnostics Inc is 13.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXDX stock?

You can check AXDX's fair value in chart for subscribers.

What is the fair value of AXDX stock?

You can check AXDX's fair value in chart for subscribers. The fair value of Accelerate Diagnostics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Accelerate Diagnostics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Accelerate Diagnostics Inc a good stock to buy?

The fair value guage provides a quick view whether AXDX is over valued or under valued. Whether Accelerate Diagnostics Inc is cheap or expensive depends on the assumptions which impact Accelerate Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXDX.

What is Accelerate Diagnostics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 27 2024, AXDX's PE ratio (Price to Earnings) is -0.21 and Price to Sales (PS) ratio is 1.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXDX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Accelerate Diagnostics Inc's stock?

In the past 10 years, Accelerate Diagnostics Inc has provided -0.379 (multiply by 100 for percentage) rate of return.